

**BRAWN**



43F7D

CIN NO.: L74899DL1985PLC022468

To,  
The Secretary,  
Listing Department,  
BSE Limited,  
Floor 25, Phirozee Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001

Date: 22-05-2019

**Sub: Outcome of 2<sup>nd</sup> / 2019- 20 Board Meeting and Submission of Audited Financial Results & Statement of Assets & Liabilities for the quarter and year ended 31.03.2019**

**SCRIP CODE: 530207**

Dear Sir,

Pursuant to provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter "SEBI Listing Regulations", this is to inform that the Board of Directors of the Company in its meeting held today, i.e. 22<sup>nd</sup> day of May, 2019 have inter—alia considered, approved and taken on record the followings:—

The audited standalone financial results along with Statement of Assets & Liabilities of the Company for the fourth quarter(Q4) and financial year ended 31<sup>st</sup> March, 2019, which was recommended by the Audit Committee at their meeting held on May 22<sup>nd</sup>, 2019, copies whereof alongwith audit report for standalone results and declaration by the Chief Financial Officer of the Company in terms of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed herewith.

The meeting of the Board of Directors was commenced at 03.00 P.M. and concluded at 05.00 P.M.

You are requested to take above on record.

Thanking you,

For **BRAWN BIOTECH LIMITED**

  
  
Priyanka Sharma  
Company Secretary \*

Encl.: As above

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*...for better life*


**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

**Works :** 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48





# BRAWN

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002						
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2019						
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-19 Audited	31-Dec-18 Un-audited	31-Mar-18 Audited	31-Mar-19 Audited	31-Mar-18 Audited
1	<b>Revenue from operations</b>					
	Revenue from operations					
	Other Income	1,542.45	2,123.36	1,570.51	6,517.90	5,578.37
	<b>Total Revenue</b>	<b>63.28</b>	<b>0.16</b>	<b>25.52</b>	<b>73.78</b>	<b>8.97</b>
2	<b>Expenses</b>	<b>1,605.73</b>	<b>2,123.52</b>	<b>1,596.03</b>	<b>6,591.68</b>	<b>5,587.34</b>
a	Cost of material consumed	-	-	-	-	-
b	Purchase of stock-in-trade	1,395.03	1,933.27	1,390.75	5,848.92	4,882.19
c	Change in inventories of finished goods, work in progress and stock in trade	(0.80)	2.34	8.24	0.90	2.46
d	Employee Benefit expenses	81.45	104.73	83.43	302.49	298.19
e	Depreciation and amortisation expenses	0.79	0.81	0.78	3.20	3.16
f	Finance Cost	2.16	2.18	1.63	6.14	5.73
g	Other expenses	91.09	43.75	79.78	249.50	199.50
	<b>Total Expenses</b>	<b>1,569.72</b>	<b>2,087.08</b>	<b>1,564.61</b>	<b>6,411.15</b>	<b>5,391.24</b>
3	<b>Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)</b>	<b>36.00</b>	<b>36.44</b>	<b>31.42</b>	<b>180.54</b>	<b>196.10</b>
4	<b>Other Income</b>	-	-	-	-	-
5	<b>Profit from ordinary activities before exceptional items (3-4)</b>	<b>36.00</b>	<b>36.44</b>	<b>31.42</b>	<b>180.54</b>	<b>196.10</b>
6	<b>Exceptional Items</b>	-	-	-	-	-
7	<b>Profit from ordinary activities before tax (5-6)</b>	<b>36.00</b>	<b>36.44</b>	<b>31.42</b>	<b>180.54</b>	<b>196.10</b>
8	<b>Tax Expenses</b>	<b>5.52</b>	<b>10.23</b>	<b>15.32</b>	<b>47.24</b>	<b>67.94</b>
9	<b>Profit (Loss) for the period from continuing operations (7-8)</b>	<b>30.49</b>	<b>26.21</b>	<b>16.10</b>	<b>133.29</b>	<b>128.16</b>
10	<b>Profit/(loss) from discontinuing operations</b>	-	-	-	-	-
11	<b>Tax expense of discontinuing operations</b>	-	-	-	-	-
12	<b>Profit/(loss) from Discontinuing operations (after tax) (10-11)</b>	-	-	-	-	-
13	<b>Profit (Loss) for the period (9+12)</b>	<b>30.49</b>	<b>26.21</b>	<b>16.10</b>	<b>133.29</b>	<b>128.16</b>
14	<b>Other Comprehensive Income</b>	<b>0.07</b>	<b>0.33</b>	<b>0.91</b>	<b>5.53</b>	<b>(2.74)</b>
	<b>Total Comprehensive Income</b>	<b>30.56</b>	<b>26.54</b>	<b>17.01</b>	<b>138.82</b>	<b>125.42</b>
15	<b>Details of equity share capital</b>	<b>300.03</b>	<b>300.03</b>	<b>300.03</b>	<b>300.03</b>	<b>300.03</b>
	Paid-up equity share capital					
	Face value of equity share capital					
16	Reserve excluding Revaluation Reserve					
17	<b>Earnings per share</b>					
i	Basic earnings per share	1.02	0.88	0.57	4.63	4.18
ii	Diluted earnings per share	1.02	0.88	0.57	4.63	4.18

**NOTES :-**

- Results for the quarter and year ended on 31st March, 2019 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 22th May, 2019.
- The Statutory Auditors carried out the audit for year ended 31st March, 2019. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone audited Financial Results for the quarter and year ended ended on 31.03-2019 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited  
Brij Raj Gupta  
Managing Director  
DIN NO. 00974969  
Date : 22-05-2019  
Place: Delhi

## BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

... for better life


**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

**Works :** 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



**BRAWN**

BRAWN BIOTECH LIMITED

CIN:L74899DL1985PLC022468

Regd Office: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

Rs. In Lacs

Particulars	Statement of Assets and Liabilities as on 31st March 2019	
	31-Mar-19 Audited	31-Mar-18 Audited
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
Property, Plant and Equipment	19.17	22.28
Financial Assets		
- Investment	-	-
- Trade Receivable	46.69	47.66
- Loan	4.60	3.14
Deferred Tax Asset (Net)	6.28	8.00
	76.75	81.08
<b>(2) Current Assets</b>		
Inventories	33.86	34.76
Financial Assets		
- Trade Receivables	1,645.77	1,505.42
- Cash and cash equivalents	54.47	39.61
- Loan	-	-
- Other Financial Assets	12.65	12.65
Current Tax Assets (Net)	154.86	109.86
Other Current Assets	273.33	473.85
	2,174.95	2,176.15
<b>TOTAL ASSETS</b>	<b>2,251.69</b>	<b>2,257.23</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity Share Capital	300.03	300.03
Other Equity	565.68	463.07
	865.71	763.10
<b>LIABILITIES</b>		
<b>(1) Non-current Liabilities</b>		
Financial Liabilities		
- Trade Payable	1.22	3.32
- Other Financial Liabilities		
Provisions	14.51	16.72
Deferred Tax liabilities (Net)	-	-
	15.72	20.05
<b>(2) Current Liabilities</b>		
Financial Liabilities		
- Trade Payables	1,034.81	1,122.85
- Other Financial Liabilities	86.46	112.78
Other current liabilities	77.72	83.16
Provisions	14.39	43.95
Current tax liabilities	156.87	111.34
	1,370.25	1,474.09
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2,251.69</b>	<b>2,257.23</b>

For and on behalf of Board  
For Brawn Biotech LimitedBrij Raj Gupta  
Managing Director  
DIN NO. 00974969  
Place : New Delhi  
Date : 22-05-2019**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48





**Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company  
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015**

To  
**The Board of Directors of  
Brawn Biotech Limited**

We have audited the quarterly financial results of **Brawn Biotech Limited** (the "Company") for the quarter ended 31<sup>st</sup> March, 2019 and the year to date results for the period 01<sup>st</sup> April 2018 to 31<sup>st</sup> March 2019 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Attention is drawn to the fact that figures for the quarter ended 31 March 2019 and the corresponding quarter ended in the previous year as reported in these annual financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

Our responsibility is to express an opinion on these financial results based on our audit of such Interim financial statements, which have been prepared in accordance with the recognition and Measurement principles laid down in Ind Accounting Standard for Interim Financial Reporting ( Ind AS 34 ), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standard generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed in financial results. An audit also includes assessing the accounting principles used and significant estimates made by the Management. We believe that our audit provides a reasonable basis for our opinion.

The comparative financial information of the company for the corresponding quarter and year ended March 31, 2018 included in these financial results, are based on the previously issued financial results prepared in accordance with the recognition and measurement principles specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India.

In our opinion and to the best of our information and according to the explanations given to us, the accompanying statement:

- (i) is presented in accordance with the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements ) Regulations, 2015 in this regard; and
- (ii) Give a true and fair view of the net profit and other financial information for the quarter and year ended 31<sup>st</sup> March 2019.

For Rajiv Udai & Associates  
Chartered Accountants  
Firm Registration No. 18764N  
  
Rajeev Jain  
(Partner)  
Membership No. 99767



Place: Delhi  
Date: 22.05.2019





# BRAWN

To,  
The Secretary  
Listing Department  
BSE Limited  
Floor 25, Phirozee Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001

Date: 22.05.2019

**Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Scrip Code: 530207**

In compliance with the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s Rajiv Udai & Associates, Chartered Accountant, Statutory Auditor of the Company have issued an Audit Report with unmodified opinion on Audited Standalone Financial Results of the Company for the Quarter and Financial year ended 31st March, 2019.

Kindly take note of the same.

Thanking you

Yours Faithfully

**For Brawn Biotech Limited**

  
Rati Garg  
Chief Financial Officer



## **BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*... for better life*

**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

**Works :** 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48